Select the option that best describes what you are looking for
Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.
Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.
Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.
Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.
Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.
Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.
Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.
Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.
Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.
Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.
Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.
Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.
Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.
Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.
Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.
Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.
Certified CRO services with NanoString GeoMx Digital Spatial Profiling.
De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.
Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.
Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.
Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.
Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.
Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.
Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.
Learn more about how our consulting services can help to support your journey to the clinic.
Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.
Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.
We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.
We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.
Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.
Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.
Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.
Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.
Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.
Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.
Liver cancer is the second leading cause of cancer-related deaths worldwide. Due to this, there is a need for more predictive and relevant preclinical models to provide better insights into clinical outcomes when evaluating new cancer therapies. Patient-derived xenograft (PDX) models display a true representation of the human genetic and phenotypic heterogeneity seen in patient populations and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. Crown Bioscience’s collection consists of a large number of liver cancer PDX models, including several orthotopic models to more closely recapitulate the tumor microenvironment. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER | CANCER TYPE | CANCER SUBTYPE | DESCRIPTION | # per page |
---|---|---|---|---|
LI0050 | Liver Cancer | HCC | Hepatocellular carcinoma from middle lobe of liver, grade IV, G4-S4, cancer embolus were observed in part of vessels, nodular cirrhosis presented surrounding liver tissues, fatty degeneration (about 10~15%) were observed. | CLICK TO VIEW |
LI0334 | Liver Cancer | HCC | Hepatic nodular cirrhosis with hepatocelluar carcinoma; chronic cholecystitis. | CLICK TO VIEW |
LI0348 | Liver Cancer | HCC | Postnecrotic cirrhosis with combined cell type carcianoma; Postnecrotic cirrhosis with mixed carcinoma of liver. | CLICK TO VIEW |
LI0574 | Liver Cancer | HCC | Hepatocellular carcinoma | CLICK TO VIEW |
LI0612 | Liver Cancer | HCC | Postnecrotic cirrhosis with hepatocellular carcinoma. Chronic cholecystitis. | CLICK TO VIEW |
LI0752 | Liver Cancer | HCC | Right lobes massive type hepatocelluar carcinoma; Hepatocellular carcinoma from liver right lobe, accompanied with necrosis, tumor mass: 14cm x 12cm x 10cm. Chronic cholecystitis, cholelithiasis. IHC result: CK(++), CK7(-), CK18(++), CK19(++), CEA(-), AFP(-). | CLICK TO VIEW |
LI0801 | Liver Cancer | HCC | Early hepatocirrhosis with hepatocarcinoma. Chronic cholecystitis. Cholelithiasis. | CLICK TO VIEW |
LI0941 | Liver Cancer | SCC | NA | CLICK TO VIEW |
LI1004 | Liver Cancer | HCC | Hepatocellular carcinoma, grade II, with nodular cirrhosis. IHC results: AFP(+), HEPA(partial +), PDEC(100%++), P48(-), CK7(-), CD34(abundant blood sinus ), CK19(-), PERK(-). | CLICK TO VIEW |
LI1005 | Liver Cancer | HCC | Hepatocellular carcinoma. Chronic cholecystitis. IHC results: AFP(+), HEPA(+), PDEC(++), P48(-), CK7(-), CD34 (massive vessel +), CK19(-), PERK(-). | CLICK TO VIEW |
LI1025 | Liver Cancer | HCC | Hepatocellular carcinoma, with necrosis, nodular cirrhosis presented in periphery liver with a small amount of hepatocyte fatty degeneration. IHC results: AFP(+), HEPA (+), PDEC(part +), CK7(bile duct +), CD34(vessel +), CK19(bile duct +), PERK(-). | CLICK TO VIEW |
LI1035 | Liver Cancer | HCC | Hepatocellular carcinoma, tumor embolus in individual vessel, fibrous tissues hyperplasia with part of fibrous septum formation. IHC results: AFP(+/-), HEPA(+), PDEC(+), PERK(-), CD34(vessel +), CK7(+), CK19(+). | CLICK TO VIEW |
LI1037 | Liver Cancer | HCC | Hepatocellular carcinoma, haemorrhage, necrosis, fibrous tissues mild hyperplasia, chronic cholecystitis, IHC results: AFP (-), HEPA (+), PDEC (-), CD34 (vessel +), CK7 (bile duct +), CK19 (bile duct +), PERK (-). | CLICK TO VIEW |
LI1054 | Liver Cancer | HCC | Epithelioid malignant tumor, consider hepatocellular carcinoma, grade II, with massive necrosis, nodular cirrhosis, fibrous tissues hyperplasia with part of fibrous septum formation, IHC results: AFP(-), HEPA (-), PDEC( little focus +), P48(-), CD34 (vessel +), CK19 (+), PERK (-), PAKT (-), PMEK1/2(-), CK7(part +). | CLICK TO VIEW |
LI1055 | Liver Cancer | HCC | Epithelioid malignant tumor, consider mixed liver cancer, hepatocellular carcinoma and adenocarcinoma of bile duct, lympha cells invade portal area with fibrous tissues hyperplasia, IHC results: AFP(-), HEPA(-), PDEC(part +), P48(-), CD34 (vessel +), CK19 (+), PERK(-), PAKT(-), PMEK1/2(-), CK7(+), CK20(part +), CEA(part +). | CLICK TO VIEW |
LI1057 | Liver Cancer | HCC | Hepatocellular carcinoma with massive necrosis, grade II-III. IHC results: AFP(-), HEPA(-), PDEC(-), P48(-), CD34(blood vessel +), CK19(biliary ducts +), CK7(biliary ducts +), PERK(-), PAKT(-), PMEK1/2(-). | CLICK TO VIEW |
LI1058 | Liver Cancer | HCC | Hepatocellular carcinoma with massive necrosis, grade II-III, lympha cells infiltrated portal area with fibrous tissues hyperplasia. IHC results: AFP(-), HEPA(-), PDEC(-), P48(-), CD34(blood vessle +), CK19(-), PERK(-), PAKT(-), CK (part +), PMEK1/2(-). | CLICK TO VIEW |
LI1068 | Liver Cancer | HCC | Hepatocellular carcinoma, tumor cells scattered within liver, tumor embolus in vessel, nodular cirrhosis presented in periphery liver. IHC results: AFP(++), HEPA(+), PDEC(-), P48(-),CD34(+), CK19(-), PERK(-), PEKT(-), PEMK1/2(-). | CLICK TO VIEW |
LI1069 | Liver Cancer | HCC | Hepatocellular carcinoma, with part of necrosis, tumor embolus in individual vessel, nodular cirrhosis presented in periphery liver. Chronic cholecystitis. IHC results: AFP(+), HEPA(+), PDEC(-), P48(-), CD34(+), CK19(+), PERK(-), PEKT(-), PEMK1/2(-). | CLICK TO VIEW |
LI1074 | Liver Cancer | HCC | Neuroendocrine carcinoma in liver. PDX pathology QC as HCC. | CLICK TO VIEW |
LI1078 | Liver Cancer | HCC | Hepatocellular carcinoma, with necrosis, tumor embolus in vessel, nodular cirrhosis presented in periphery liver. IHC results: AFP(+), HEPA(+), PDEC(-), P48(-), CD34(+), CK19(+), PERK(-), PAKT(-), PEMK1/2(-), CK7(-). | CLICK TO VIEW |
LI1081 | Liver Cancer | HCC | Hepatocellular carcinoma, diffuse in liver, cancer embolus in vessel. IHC results: AFP(<5%+), HEPA(100%+++), CD34(massive vessel), CK19(-), PDEC(10%+), p53(20%++-+++), EGFR(-), HER2(<5%+), Ki-67(about 15%++). | CLICK TO VIEW |
LI1088 | Liver Cancer | HCC | Hepatocellular carcinoma, with necrosis, cancer embolus in vessel, G2S2. IHC results: AFP(+), HEPA(+), PDEC(-), P48(-), CD34 (vessel +), CK7(bile duct +), CK19(bile duct +), PERK(-), hTERT(-), LYVE-1(-). | CLICK TO VIEW |
LI1097 | Liver Cancer | HCC | Hepatocellular carcinoma of middle lobe, grade II-III, peripheral hepatic tissue G2S4. Chronic cholecystitis. Cholecyslithiasis. | CLICK TO VIEW |
LI1098 | Liver Cancer | HCC | Hepatocellular carcinoma of right lobe, grade II, peripheral hepatic tissue G1S1. | CLICK TO VIEW |
LI11482 | Liver Cancer | NA | NA | CLICK TO VIEW |
LI1549 | Liver Cancer | NA | Nodular cirrhosis with hepatocellular carcinoma. | CLICK TO VIEW |
LI1646 | Liver Cancer | HCC | Nodular cirrhosis with hepatocellular carcinoma, hemorrhagic necrosis. | CLICK TO VIEW |
LI2169 | Liver Cancer | HCC | Hepatocellular carcinoma, moderately to poorly differentiated. Tumor size: 4X 3.5X 3cm. IHC results: AFP(part cells, +), CD34(+), CK18(+), CK19(-), CK7(several cells +), CK8(+), EMA(several cells +), hepatocyte(+). | CLICK TO VIEW |
LI2231 | Liver Cancer | ADC | N/A | CLICK TO VIEW |
LI2800 | Liver Cancer | Adenocarcinoma | NA | CLICK TO VIEW |
LI2842 | Liver Cancer | Adenocarcinoma | NA | CLICK TO VIEW |
LI2893 | Liver Cancer | NA | NA | CLICK TO VIEW |
LI3205 | Liver Cancer | HCC | Hepatocellular carcinoma, Edmondson III | CLICK TO VIEW |
LI3243 | Liver Cancer | HCC | NA | CLICK TO VIEW |
LI5129 | Liver Cancer | HCC | liver carcinoma hepatocellular carcinoma. Pathol comment: c/w diagnosis. approximately 80% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. | CLICK TO VIEW |
LI5130 | Liver Cancer | HCC | liver carcinoma sarcomatoid hepatocellular carcinoma. Pathol comment: c/w diagnosis. approximately 80% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. | CLICK TO VIEW |
LI5131 | Liver Cancer | ADC | N/A | CLICK TO VIEW |
LI5132 | Liver Cancer | HCC, fibrolamellar type | hepatocellular carcinoma, metastatic hepatocellular carcinoma, fibrolamellar type. Pathol comment: c/w diagnosis. approximately 25% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. | CLICK TO VIEW |
LI6206 | Liver Cancer | NEC | Liver: poorly differentiated neuroendocrine carcinoma. Please exclude metastatic carcinoma based on clinical information and medical history. | CLICK TO VIEW |
LI6278 | Liver Cancer | HCC | N/A | CLICK TO VIEW |
LI6280 | Liver Cancer | NEC? HCC? | Right lobe of liver: hepatocellular carcinoma, spindle cell type, grade III, with sarcomatoid type and mixed type cirrhosis. | CLICK TO VIEW |
LI6281 | Liver Cancer | HCC | N/A | CLICK TO VIEW |
LI6291 | Liver Cancer | NA | NA | CLICK TO VIEW |
LI6292 | Liver Cancer | NA | NA for clinical diagnosis info. | CLICK TO VIEW |
LI6293 | Liver Cancer | HCC | Hepatocellular carcinoma, grade III | CLICK TO VIEW |
LI6294 | Liver Cancer | HCC | Hepatocellular carcinoma, grade III | CLICK TO VIEW |
LI6295 | Liver Cancer | HCC | N/A | CLICK TO VIEW |
LI6297 | Liver Cancer | HCC | Hepatocellular carcinoma, grade III | CLICK TO VIEW |
LI6301 | Liver Cancer | HCC | NA | CLICK TO VIEW |
LI6306 | Liver Cancer | HCC | Intrahepatic cholangiocarcinoma, moderately differentiated | CLICK TO VIEW |
LI6601 | Liver Cancer | HCC | Left lobe of liver: cholangiocarcinoma, grade II-III, periphery hepatic tissues, G1S3. Pathology QC on PDX as HCC. | CLICK TO VIEW |
LI6610 | Liver Cancer | HCC | Left lobe of liver: hepatocellular carcinoma, grade II-III, peripheral hepatic tissues show nodular cirrhosis G2S4. IHC result: AFP(-), Hepa(+), CD34(abundant blood sinus), CK19(-), CK7(partial cells +), KI67(15%+), Thromblin(partial cells +), GP73(100%+++), CD8(about 5/HPF), CD151(-), OPN(90%+), IL-2(-). | CLICK TO VIEW |
LI6611 | Liver Cancer | HCC | Cholangiocarcinoma. Pathology QC: HCC with massive necrosis (P5, P6) | CLICK TO VIEW |
LI6612 | Liver Cancer | HCC | Right lobe of liver: hepacellular carcinoma, grade II, with hemorrhagic necrosis. Peripheral hepatic tissues showed nodular cirrhosis G1-2S4e. IHC result: AFP(++), Hepa(+), CK7(-), CK19(-), CD34(abundant blood sinus), GP73(+), Thromblin(+), IL-2(focal +), KI67(30%+), CD8(about 10/HPF), OPN(-), CD56(-), CD117(-). | CLICK TO VIEW |
LI6615 | Liver Cancer | HCC | Righr lobe of liver: hepatocellular carcinoma, grade II-III, with haemorrhagia necrosis. Peripheral hepatic tissues showed nodular cirrhosis G1-2S4. | CLICK TO VIEW |
LI6616 | Liver Cancer | HCC | Left lobe of liver: hepatocellular carcinoma, grade II-III, with massive necrosis. Peripheral hepatic tissues showed nodular cirrhosis G2S3. | CLICK TO VIEW |
LI6617 | Liver Cancer | HCC | Mixed carcinoma of liver (HCC and Cholangiocarcinoma) | CLICK TO VIEW |
LI6619 | Liver Cancer | HCC | Right lobe of liver: hepacellular carcinoma, grade II-III. Peripheral hepatic tissues showed nodular cirrhosis G2S2. IHC result: AFP(++), Hepa(++), CK7(few +), CK19(70%+), CD34(abundant blood sinus), GPC3(100%+), KI67(80%+), CD8(about 20/HPF), CD151(-), GS(100%++), HSP70(80%+), CD56(-), CD117(-). | CLICK TO VIEW |
LI6622 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II-III. IHC results: AFP(-), Hepa(100%+++), CD34(abundant blood vessel), CK19(-), CK7(-), KI67(50%+), Thromblin(90%++), GP73(100%+++), CD8(30/HPF), IL-2(-), CD151(-), OPN(-). | CLICK TO VIEW |
LI6628 | Liver Cancer | Mixed carcinoma of liver (HCC and Cholangiocarcinoma) | Right lobe of liver: poorly differentiated adenocarcinoma, stromal invasion and massive necrosis could be seen, accorded with mixed carcinoma of hepatocellular carcinoma and cholangiocarcinoma based on morphology, clinical information and IHC results. Peripheral hepatic tissues showed nodular cirrhosis G2S4 (hepatocyte fatty degeneration <5%). | CLICK TO VIEW |
LI6643 | Liver Cancer | HCC | Liver: hepatocellular carcinoma, grade III, with necrosis. Peripheral hepatic tissues showed nodular cirrhosis G2S4F0. IHC results: AFP(-), Hepa(-), CK7(5%+), CK19(5%+), CD34(abundant blood vessel), KI67(40%+), GS(80%++), GPC-3(80%++), HSP70(60%+~++). | CLICK TO VIEW |
LI6646 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II-III. Peripheral hepatic tissues showed nodular cirrhosis. IHC results: AFP(-), Hepa(-), CD34(blood vessel +), CK19(90%+), CK7(5%+), KI67(40%+), Thromblin(-), GP73(100%+++), CD8(20/HPF), IL-2(10%+), CD151(-), OPN(70%+), CD68(histocyte +). | CLICK TO VIEW |
LI6649 | Liver Cancer | HCC | NA | CLICK TO VIEW |
LI6650 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma with necrosis, grade II-III. Peripheral hepatic tissues showed nodular cirrhosis G2S4. | CLICK TO VIEW |
LI6652 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II-III. | CLICK TO VIEW |
LI6653 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II, with necrosis. Peripheral hepatic tissues showed nodular cirrhosis G2-3S4. IHC results: AFP(focal +), Hepa(part +), CK7(-), CK19(+++), CD34(abundant blood sinus) KI67(70%+), HSP70(++), GPC3(part +), SYN(-), CHG(-), CD56(-). | CLICK TO VIEW |
LI6654 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II. Peripheral hepatic tissues showed nodular cirrhosis with fatty degeneration (35%). | CLICK TO VIEW |
LI6656 | Liver Cancer | HCC | Left lobe of liver: hepatocellular carcinoma, grade II. Peripheral hepatic tissues showed nodular cirrhosis G2S4. | CLICK TO VIEW |
LI6659 | Liver Cancer | HCC | NA | CLICK TO VIEW |
LI6660 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II. Peripheral hepatic tissues showed nodular cirrhosis. IHC results: AFP(-), Hepa(100%+++), CD34(massive blood vessel), CK19(-), CK7(10%+), Ki67(20%+), Thromblin(30%+), GP73(100%+++), CD8(10/HPF), IL-2(-), CD151(-), OPN(90%+), CD68(histocyte +). | CLICK TO VIEW |
LI6662 | Liver Cancer | HCC | Special hepatic segments: hepatocellular carcinoma, grade II, cancer embolus present in vessel. Peripheral hepatic tissues showed hodular cirrhosis G2S4. IHC result: AFP(-), Hepa(80%++), CK7(-), CK19(-), CD34(abundant blood sinus), GPC3(80%+), KI67(10%+), GS(100%+~++), HSP70(70%++). | CLICK TO VIEW |
LI6663 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II-III, with massive necrosis. IHC results: AFP(50%+), Hepa(50% weak +), CK7(5%+), CK19(100%++), CD34(abundant blood sinus), GPC3(40%+), KI67(40%+), CD8(5 /HPF), OPN(10%+), CD151(-), ARG-1(30%+), CD56(small +), CD117(-). | CLICK TO VIEW |
LI6664 | Liver Cancer | HCC | Right lobe of liver: mixed hepatocellular carcinoma, moderately differentiated. Cancer embolus presents in many vessels, periphery hepatic tissues: G1S2. IHC results: c-Met(++), CD151(cell nucleus +), CD34(abundant blood sinus), CK19(++), CD56(-), KI67(80%+), EPCAM(membrane +), B-cat(membrane +), OPN(-). | CLICK TO VIEW |
LI6665 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II, with massive necrosis. Peripheral hepatic tissues showed hodular cirrhosis G2S4. IHC results: AFP(-), Hepa(+), CK7(-), CK19(-), CD34(abundant blood sinus), KI67(40%+), CD8(50/HPF), OPN(90%+), EPCAM(-), GP73(100%++), ARG-1(60%+), CD56(-), CD117(-). | CLICK TO VIEW |
LI6668 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II-III. Peripheral hepatic tissues showed hodular cirrhosis G1S4. | CLICK TO VIEW |
LI6669 | Liver Cancer | HCC | Transcoelomic metastasis foci of abdominal cavity: malignant epithelial tumor, accorded with hepatocellular carcinoma based on medical history and IHC results, grade II-III, with necrosis. IHC results: AFP(focal +), Hepa(focal+), CK7(-), CK19(disperse +),CD34(blood vessel +), KI67(70%+), GS(++), HSP70(+++), GPC3(focal +), CD56(-), CD117(-). | CLICK TO VIEW |
LI6671 | Liver Cancer | ADC? HCC? | Middle lobe of liver and gall bladder: poorly differentiated adenocarcinoma. Consider gall bladder carcinoma on the basis of IHC results. One of four lymph node involved by metastatic carcinoma (1/4). | CLICK TO VIEW |
LI6674 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma, grade II-III, with necrosis. Peripheral hepatic tissues showed hodular cirrhosis G2-3S4. All lypho nodes are benign (0/7). IHC results: AFP(20%+), Hepa(40%+), CK7(-), CK19(2%+), CD34(abundant blood sinus), GP73(70%+), Thromblin(10%+), KI67(70%+), CD8(20/HPF), OPN(40%+), CD56(scattered +),CD117(scattered +) | CLICK TO VIEW |
LI6675 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma with massive necrosis, grade II-III. Peripheral hepatic tissues showed hodular cirrhosis G2S3. | CLICK TO VIEW |
LI6676 | Liver Cancer | HCC | Special hepatic segments: hepatocellular carcinoma, grade II-III, cancer embolus present in vessel. Peripheral hepatic tissues showed hodular cirrhosis G3S4. | CLICK TO VIEW |
LI6677 | Liver Cancer | HCC | Right lobe of liver: hepatocellular carcinoma with necrosis, grade II. Peripheral hepatic tissues showed hodular cirrhosis G2S4. | CLICK TO VIEW |
LI6680 | Liver Cancer | ADC? HCC? | Right lobe of liver: cholangiocarcinoma with necrosis, grade II-III, cancer embolus present in vessel. | CLICK TO VIEW |
LI6683 | Liver Cancer | HCC | Left lobe of liver: hepatocellular carcinoma, grade III, cancer embolus present in vessel. Peripheral hepatic tissues showed hodular cirrhosis G2S4. | CLICK TO VIEW |
LI6686 | Liver Cancer | HCC | Caudate lobe of liver: hepatocellular carcinoma, grade II-III, cancer embolus present in vessel. Peripheral hepatic tissues showed hodular cirrhosis G1S4. | CLICK TO VIEW |
LI6687 | Liver Cancer | NA | Right lobe of liver: hepatocellular carcinoma with necrosis, grade III. Peripheral hepatic tissues showed hodular cirrhosis G2S2. | CLICK TO VIEW |
LI6688 | Liver Cancer | HCC | Left lobe of liver: hepatocellular carcinoma, grade III. Peripheral hepatic tissues did not form hodular cirrhosis G1S2. | CLICK TO VIEW |
LI6691 | Liver Cancer | HCC | Right lobel of liver: mixed carcinoma of liver, mdoerately differentiated hepatocellular carcinoma mixed moderately differentiated cholangiocellular carcinoma. Peripheral hepatic tissues showed nodular cirrhosis G1S1 | CLICK TO VIEW |
LI6692 | Liver Cancer | NA | Right posterior lobe of liver: poorly differentiated hepatocellular carcinoma with neuroendocrine differentiation. Peripheral hepatic tissues showed hodular cirrhosis G1S3-4. | CLICK TO VIEW |
LI6699 | Liver Cancer | HCC | N/A | CLICK TO VIEW |
LI6700 | Liver Cancer | HCC | Left lobel of liver: hepatocellular carcinoma, grade III. Peripheral hepatic tissues showed nodular cirrhosis G2S4. | CLICK TO VIEW |
LI6708 | Liver Cancer | HCC | Right lobel of liver: hepatocellular carcinoma, grade III. Peripheral hepatic tissues showed nodular cirrhosis G2S2. | CLICK TO VIEW |
LI6716 | Liver Cancer | HCC | NA for clinical diagnosis info. Pathology QC: Hepatocellular carcinoma. | CLICK TO VIEW |
LI6717 | Liver Cancer | HCC | NA for clinical diagnosis info. Pathology QC: Hepatocellular carcinoma. | CLICK TO VIEW |
LI6718 | Liver Cancer | HCC | NA for clinical diagnosis info. Pathology QC: Hepatocellular carcinoma. | CLICK TO VIEW |
LI6722 | Liver Cancer | HCC | Right lobe of liver: poorly differentiated adenocarcinoma, consider poorly differentiated cholangiocarcinoma on basis of IHC results. Peripheral hepatic tissues showed nodular cirrhosis (G2S4). | CLICK TO VIEW |
LI6723 | Liver Cancer | HCC | Section IV of liver: hard to distinguish between poorly differentiated hepatocellular carcinoma and cholangiocarcinoma, considre as poorly differentiated hepatocellular carcinoma | CLICK TO VIEW |
LI9323 | Liver Cancer | NA | NA | CLICK TO VIEW |
Already Registered? Login
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy